Subject has documented typical atrial flutter.
Subject has any history of successful or unsuccessful treatment of AF with class I or III antiarrhythmic or sotalol with the intention to prevent an AF recurrence. Patients pretreated with above AAD at maximum 48 hours with the intention to convert an AF episode are allowed.
Subject had any previous left atrial ablation.
Subject had any previous cardiac surgery, e.g. prosthetic valves.
Subject has permanent pacemaker or defibrillator implant.
Subject has 2° type II, 3° degree AV-block or left/right bundle branch block pattern.
Subject has unstable angina pectoris.
Subject has history of previous myocardial infarction or percutaneous intervention during the last three months.
Subject has symptomatic carotid stenosis.
Subject has chronic obstructive pulmonary disease with detected pulmonary hypertension or any other evidence of significant lung disease.
Subject has any contraindication for oral anticoagulation.
Subject has any history of previous transient ischemic attack or stroke.
Subject has known intra-cardiac thrombus formation.
Subject has any significant congenital heart defect corrected or not (except for patent foramen ovale that is allowed).
Subject has evidence of congestive heart failure (NYHA class II, III or IV) in sinus rhythm.
Subject has hypertrophic cardiomyopathy.
Subject has abnormal long or short QT interval, signs of Brugada syndrome, known inheriting ion channel disease on the family, arrhythmogenic right ventricular dysplasia.
Subject has sarcoidosis.
Subject has pulmonary vein stent.
Subject has myxoma. Exclusion criteria based on laboratory abnormalities
Subject has thrombocytosis (platelet count > 600,000 / µl) or thrombocytopenia (platelet count <100,000 / µl).
Subject has any untreated or uncontrolled hyperthyroidism or hypothyroidism.
Subject has renal dysfunction with glomerular filtration rate < 60 ml / min.
Subject has known cryoglobulinaemia. General exclusion criteria
Subject has a reversible causes for AF like hyperthyroidism and alcoholism.
Subject is a pregnant woman or woman of childbearing potential not on adequate birth control: only woman with a highly effective method of contraception [oral contraception or intra-uterine device] (who must have a negative pregnancy test within 1 week of the start of the therapy) or sterile woman can be enrolled.
Subject is a breastfeeding woman.
Subject has an active systemic infection.
Subject is employed by Medtronic or by the department of any of the investigators or is a close relative of any of the investigators.
Subject is unwilling or unable to comply fully with study procedures and follow-up due to any disease condition, which can raise doubt about compliance and influencing the study outcome especially any kind of cancer, severe bleeding in history or a suspected pro-coagulant state.
Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures and follow up.
Subject has a life expectancy of = 1 year.
Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.

NCT01803438_exc_T1
Condition
atrial flutter
NCT01803438_exc_T3
Condition
AF
NCT01803438_exc_T4
Drug
antiarrhythmic
NCT01803438_exc_T5
Drug
sotalol
NCT01803438_exc_T6
Qualifier
class I
NCT01803438_exc_T7
Qualifier
lass II
NCT01803438_exc_T8
Scope
class I or III
NCT01803438_exc_T10
Scope
antiarrhythmic or sotalol
NCT01803438_exc_T2
Procedure
atrial ablation
NCT01803438_exc_T11
Qualifier
left
NCT01803438_exc_T12
Procedure
cardiac surgery
NCT01803438_exc_T13
Device
prosthetic valves
NCT01803438_exc_T14
Device
permanent pacemaker
NCT01803438_exc_T15
Device
defibrillator implant
NCT01803438_exc_T16
Condition
3° degree AV-block
NCT01803438_exc_T17
Condition
pe II, 3° ock or l
NCT01803438_exc_T18
Condition
right bundle branch block
NCT01803438_exc_T19
Condition
righ e branch block patt
NCT01803438_exc_T20
Condition
unstable angina pectoris
NCT01803438_exc_T21
Condition
myocardial infarction
NCT01803438_exc_T22
Procedure
percutaneous intervention
NCT01803438_exc_T23
Temporal
last three months
NCT01803438_exc_T24
Scope
myocardial infarction or percutaneous intervention
NCT01803438_exc_T25
Condition
carotid stenosis
NCT01803438_exc_T26
Qualifier
symptomatic
NCT01803438_exc_T27
Condition
chronic obstructive pulmonary disease
NCT01803438_exc_T28
Condition
pulmonary hypertension
NCT01803438_exc_T29
Condition
lung disease
NCT01803438_exc_T30
Qualifier
significant
NCT01803438_exc_T31
Scope
pulmonary hypertension or any other evidence of significant lung disease
NCT01803438_exc_T32
Condition
contraindication
NCT01803438_exc_T33
Drug
oral anticoagulation
NCT01803438_exc_T34
Condition
transient ischemic attack
NCT01803438_exc_T35
Condition
stroke
NCT01803438_exc_T36
Condition
intra-cardiac thrombus
NCT01803438_exc_T37
Condition
congenital heart defect
NCT01803438_exc_T38
Qualifier
significant
NCT01803438_exc_T39
Negation
except
NCT01803438_exc_T40
Condition
patent foramen ovale
NCT01803438_exc_T41
Condition
congestive heart failure
NCT01803438_exc_T42
Measurement
NYHA class
NCT01803438_exc_T43
Value
II
NCT01803438_exc_T44
Value
III
NCT01803438_exc_T45
Value
IV
NCT01803438_exc_T46
Condition
sinus rhythm
NCT01803438_exc_T47
Scope
II, III or IV
NCT01803438_exc_T48
Condition
hypertrophic cardiomyopathy
NCT01803438_exc_T49
Measurement
QT interval
NCT01803438_exc_T50
Qualifier
abnormal
NCT01803438_exc_T51
Value
long
NCT01803438_exc_T52
Value
short
NCT01803438_exc_T53
Condition
Brugada syndrome
NCT01803438_exc_T54
Condition
inheriting ion channel disease
NCT01803438_exc_T55
Observation
inheriting ion channel disease on the family
NCT01803438_exc_T56
Condition
right ventricular dysplasia
NCT01803438_exc_T57
Qualifier
arrhythmogenic
NCT01803438_exc_T58
Scope
long or short
NCT01803438_exc_T59
Condition
sarcoidosis
NCT01803438_exc_T60
Device
pulmonary vein stent
NCT01803438_exc_T61
Condition
myxoma
NCT01803438_exc_T63
Condition
thrombocytosis
NCT01803438_exc_T64
Measurement
platelet count
NCT01803438_exc_T65
Value
> 600,000 / µl
NCT01803438_exc_T66
Condition
thrombocytopenia
NCT01803438_exc_T67
Measurement
platelet count
NCT01803438_exc_T68
Value
<100,000 / µl
NCT01803438_exc_T69
Condition
hyperthyroidism
NCT01803438_exc_T70
Condition
hypothyroidism
NCT01803438_exc_T71
Qualifier
untreated
NCT01803438_exc_T72
Qualifier
uncontrolled
NCT01803438_exc_T73
Scope
hyperthyroidism or hypothyroidism
NCT01803438_exc_T74
Scope
untreated or uncontrolled
NCT01803438_exc_T75
Condition
renal dysfunction
NCT01803438_exc_T76
Measurement
glomerular filtration rate
NCT01803438_exc_T77
Value
< 60 ml / min
NCT01803438_exc_T78
Condition
cryoglobulinaemia
NCT01803438_exc_T79
Condition
hyperthyroidism
NCT01803438_exc_T80
Condition
alcoholism
NCT01803438_exc_T83
Condition
systemic infection
NCT01803438_exc_T84
Qualifier
active
NCT01803438_exc_T88
Observation
life expectancy
NCT01803438_exc_T89
Value
= 1 year